国药泽华夏 太极济苍生 2025 年度环境、社会及治理（ESG）报告 Environmental,SocialandGovernanceReport 01 重庆太极实业（集团）股份有限公司 CHONGQINGTAIJIINDUSTRY(GROUP)CO.,LTD. 太 极 集 团 公 众 号 太 极 集 团 视 频 号 2025 年度环境、社会及治理（ESG）报告 地址 重庆市两江新区恒山东路18号 邮编 401123 电话 023-89886129 邮箱 tjzq@sinopharm.com 目录 | 关于本报告 | 02 | 2025 年度荣誉 | 12 | | --- | --- | --- | --- | | 董事长致辞 | 04 | ESG 管理 | 16 | | 走进太极集团 | 06 | 责任聚焦：技术突破，引领健康产业高质量发展 | 22 | 持规恒进 引领药企新发展 绿色生产 履行低碳新担当 产业联动 构建医药新生态 以人为本 1 2 3 共绘和谐新生活 4 推进党建引领 32 完善公司治理 36 夯实药品质量 44 深化绿色运营 62 加强环境管理 65 应对气候变化 72 可持续供应链 ...

重庆太极实业（集团）股份有限公司全体股东： 我们审计了重庆太极实业（集团）股份有限公司(以下简称"太极 集团公司")2025 年度的财务报表，包括 2025 年 12 月 31 日的合并及 母公司资产负债表、2025 年度合并及母公司利润表、合并及母公司 现金流量表、合并及母公司所有者权益变动表和相关财务报表附注， 并于 2025 年 3 月 27 日出具了报告号为信会师报字[2026]第 ZG10390 号的无保留意见审计报告。 关于重庆太极实业（集团）股份有限公司 2025 年度 涉及财务公司关联交易的专项说明 信会师报字[2026]第 ZG10387 号 关于重庆太极实业（集团）股份有限公司 2025 年度 涉及财务公司关联交易的专项说明 信会师报字[2026]第 ZG10387 号 太极集团公司管理层根据中国证券监督管理委员会《关于规范上 市公司与企业集团财务公司业务往来的通知》（证监发〔2022〕48 号）和《上海证券交易所上市公司自律监管指引第 5 号——交易与关 联交易》的相关规定编制了后附的太极集团公司 2025 年度涉及财务 公司关联交易汇总表（以下简称"财务公司关联交易汇总表"）。 编制财 ...

证券代码：600129 证券简称：太极集团 公告编号：2026-018 重庆太极实业（集团）股份有限公司 关于召开2025年年度股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东会类型和届次 2025年年度股东会 召开的日期时间：2026 年 5 月 12 日 14 点 00 分 召开地点：重庆市两江新区恒山东路 18 号公司银杏楼 1201 会议室 (五) 网络投票的系统、起止日期和投票时间。 1 股东会召开日期：2026年5月12日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 (四) 现场会议召开的日期、时间和地点 (七) 涉及公开征集股东投票权 无 二、 会议审议事项 本次股东会审议议案及投票股东类型 | 序号 | | 议案名称 | 投票股东 类型 | | --- | --- | --- | --- | | | | | 股股东 ...

证券代码：600129 证券简称：太极集团 公告编号：2026-010 重庆太极实业（集团）股份有限公司 第十届董事会第三十七次会议决议公告 重庆太极实业（集团）股份有限公司（以下简称：公司）第十届 董事会第三十七次会议于 2026 年 3 月 15 日以邮件方式发出书面通知， 于 2026 年 3 月 25 日以现场及视频方式召开。本次会议由董事长俞敏 先生主持，会议应到董事 13 人，实到董事 13 人，公司部分高级管理 人员列席了会议。本次会议的召集、召开程序符合《公司法》和《公 司章程》的有关规定，会议合法有效。会议审议并通过了如下议案： 一、公司《2025 年度董事会工作报告》 表决情况：同意 13 票，弃权 0 票，回避 0 票，反对 0 票；表决 结果：通过。 该议案尚须提交公司股东会审议。 二、公司《2025 年年度报告及年度报告摘要》（具体内容详见公 司披露的《2025 年年度报告及年度报告摘要》） 该议案财务报告部分已经公司第十届董事会审计委员会第二十 次会议审议通过。 表决情况：同意 13 票，弃权 0 票，回避 0 票，反对 0 票；表决 结果：通过。 三、关于公司 2025 年度利润 ...

证券代码：600129 证券简称：太极集团 公告编号：2026-011 重庆太极实业（集团）股份有限公司 关于公司2025 年度拟不进行利润分配的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 公司 2025 年 9 月实施股份回购计划，回购公司股份 547.26 万股， 使用回购金额 1.2 亿元，占 2025 年度合并报表中归属于上市公司股 东的净利润的比例 99.53%。根据证监会公告〔2025〕5 号《上市公司 1 股份回购规则》（2025 修订）第十八条上市公司以现金为对价，采 用要约方式、集中竞价方式回购股份的，视同上市公司现金分红，纳 入现金分红的相关比例计算。 重要内容提示： ●重庆太极实业（集团）股份有限公司(以下简称：公司)2025 年度不进行利润分配，即不派发现金红利，不送股和资本公积金转增 股本。 ●本次利润分配已经公司第十届董事会第三十七次会议审议通过， 尚需提交公司 2025 年年度股东会审议。 ●公司不触及《上海证券交易所股票上市规则（2024 年 4 月修订）》 （以下简称《股票上市规则 ...

Group 1: Policy and Industry Development - The central government emphasizes the acceleration of traditional Chinese medicine (TCM) innovation and the quality upgrade of the Chinese medicine industry, aiming to build a health-oriented society by 2025 [4] - The Ministry of Industry and Information Technology and eight other ministries released a plan for high-quality development of the Chinese medicine industry from 2026 to 2030, focusing on enhancing the supply chain, digitalization, and green development [4] - The plan aims to cultivate leading enterprises in the TCM industry and establish high-standard raw material production bases, which will increase industry compliance and concentration, benefiting companies with strong quality control and R&D capabilities [4] Group 2: Company Strategy and Operations - The company is focusing on its core pharmaceutical business, divesting idle assets, and enhancing management efficiency by liquidating subsidiaries and transferring stakes [5] - The company aims to drive growth through "technology innovation" and "marketing innovation," strengthening its industrial marketing system and accelerating the development of major products and new drug innovations [5] - The company has announced a projected net profit of approximately 11 million yuan for 2025, representing a year-on-year increase of about 313%, with a non-recurring profit of around 6.2 million yuan due to asset disposals and government subsidies [6][7] Group 3: Performance Recovery - The company is experiencing a recovery in performance after facing adverse factors, with expectations of returning to a rapid growth trajectory [7] - Sales and revenue of major products have declined year-on-year due to policy impacts and inventory digestion, but the company is focusing on operational control and cost reduction to stabilize quality [6][7]

Group 1: Macro Analysis - The February US inflation data remains stable, indicating a mild transmission of tariffs. With recent tariff rate reductions and the time lag of previous transmission effects, it is expected that the impact of tariffs will peak in the first half of this year. However, the current data does not reflect the recent surge in oil prices, leading to market concerns about future inflation performance. If oil prices remain high at $80-90 per barrel for the next three months, it is projected to push the US CPI up by 0.3-0.4 percentage points, raising the reading to 3%-3.2%, which may restrict the Federal Reserve's rate cut operations in the short term [2]. Group 2: Industry Research - The demand for PCB drilling needles is expected to increase significantly due to the introduction of orthogonal backplane solutions in Nvidia's upcoming Rubin Ultra NVL576 architecture, replacing traditional copper cable connections. The core proposed solution currently involves "78-layer M9 resin + HVLP3/4 copper foil + Q cloth." The impact on PCB drilling needles includes: 1) a noticeable increase in consumption, 2) a rise in demand for high aspect ratio drilling needles, and 3) an increase in demand due to stringent back-drilling processes. Companies to watch in the high-end PCB drilling needle sector include Ding Tai High-Tech and World [3]. Group 3: Company Research - Tianqi Materials (002709.SZ) is expected to see a significant increase in lithium battery material demand, leading to an upward revision of profit forecasts for 2026-2028. The projected net profits for 2026, 2027, and 2028 are 6.179 billion (up 325%), 7.525 billion (up 277%), and 9.684 billion yuan, respectively, translating to EPS of 3.04, 3.70, and 4.76 yuan per share. The company maintains a "buy" rating [4]. - Jitu Express (1519.HK) is in a phase of scale expansion and accelerated profitability. The company has a solid foundation in Southeast Asia, with emerging markets (Latin America, Middle East) replicating its success, becoming a second growth engine. Strategic improvements in the Chinese market and the "anti-involution" policy are expected to boost single-ticket revenue, reinforcing the trend of profit recovery. The adjusted net profit forecasts for 2025-2027 are $4.12 million, $6.54 million, and $8.67 million, respectively, leading to a "buy" rating [5]. - Taiji Group (600129.SH) is focusing on its pharmaceutical core business, emphasizing "technological innovation" and "marketing innovation" as dual engines. The adverse effects of pharmaceutical policies and inventory digestion are expected to diminish, with the company's operating performance having bottomed out and beginning to recover. The net profit forecasts for 2025 and 2026 have been adjusted to 111 million and 213 million yuan, respectively, with a new forecast of 377 million yuan for 2027, leading to a downgrade to "hold" rating [7].

Investment Rating - The report assigns a rating of "Accumulate" to the company, reflecting a downward adjustment from previous ratings [4][6]. Core Insights - The company is expected to experience a significant rebound in its operating performance, with a projected net profit of approximately 110 million yuan for 2025, representing a year-on-year increase of about 313% [4]. - The company is focusing on its core pharmaceutical business while enhancing management efficiency and innovation through the disposal of non-core assets and subsidiaries [3][4]. - Recent policies promoting the development of traditional Chinese medicine are anticipated to benefit leading companies in the industry, enhancing compliance and quality control [2]. Summary by Sections Company Overview - The company is undergoing a transformation by divesting non-core assets and subsidiaries, including the liquidation of certain subsidiaries and the management of stakes in other companies [3]. Financial Performance - The company forecasts a net profit of 110 million yuan for 2025, with a significant increase in net profit margin expected [4]. - The anticipated non-recurring gains of approximately 62 million yuan will impact the overall financial results [4]. Market Position and Strategy - The company is committed to innovation in both technology and marketing, aiming to strengthen its industrial marketing system and enhance product development [3]. - The focus on core competencies and operational efficiency is expected to stabilize and improve the company's market position [4]. Future Outlook - The company is projected to return to a growth trajectory, with net profit estimates for 2026 and 2027 at 213 million yuan and 377 million yuan, respectively [4]. - The ongoing reforms in the healthcare sector and the reduction of social inventory for certain products are expected to positively influence sales and revenue in the coming years [4].

Core Viewpoint - Chongqing Taiji Industrial (Group) Co., Ltd. held its first extraordinary shareholders' meeting of 2026 on February 27, 2026, where two significant proposals were approved, focusing on related party transactions and the extension of commitments regarding competition issues [1] Group 1: Shareholders' Meeting Details - The meeting was chaired by Chairman Yu Min, with participation from several directors and senior management [1] - A total of 1,237 shareholders and proxies attended the meeting, representing approximately 89.37 million shares with voting rights, which accounts for 23.1910% of the total voting shares [1] - The meeting's convening, holding, and voting procedures complied with the Company Law and the Articles of Association, with legal opinions provided by Taihe Tai (Chongqing) Law Firm confirming the legality and validity of the resolutions [1] Group 2: Approved Proposals - The first proposal regarding the estimated daily related party transaction limit for 2026 was approved, with related shareholders, including Taiji Group Co., Ltd., abstaining from voting on approximately 166 million shares [1] - The second proposal concerning the actual controller's extension of commitments to avoid competition was also approved, establishing a new timeline for addressing historical competition issues [1]

证券代码：600129 证券简称：太极集团 公告编号：2026-009 重庆太极实业（集团）股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 1,237 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 89,365,094 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 23.1910 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次股东会由董事会召集，董事长俞敏先生主持，本次会议的召集、召开及 表决方式均符合《公司法》及《公司章程》的有关规定。 (五) 公司董事和董事会秘书的列席情况 1、公司在任董事13人，列席13人； 1 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (一) 股东会召开的时间：2026 年 2 月 27 日 (二) 股东会召开的地点：重庆市两江新区恒山东路 18 号公司 1 ...